IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa & Type IIb Dyslipidaemia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Lipid Regulating Agents; Rosuvastatin Calcium; Simvastatin

Criteria

Inclusion Criteria:

• Fasting low density lipoprotein level as defined by the protocol.

• Fasting triglyceride level as defined by the protocol.

Exclusion Criteria:

• The use of lipid lowering drugs or dietary supplements after Visit 1.

• Active arterial disease eg Unstable angina, or recent arterial surgery

• Blood creatine levels above the limits defined in the protocol or +4 proteinuria during dietary lead in period.

• Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.